Suchergebnisse - "IRINOTECAN"

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Autoren: Zhang Z Sun X Liu A et al.

Quelle: Cancer communications (London, England) [Cancer Commun (Lond)] 2025 Nov; Vol. 45 (11), pp. 1417-1430. Date of Electronic Publication: 2025 Sep 03.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE

MeSH-Schlagworte: Glucuronosyltransferase*/genetics , Irinotecan*/administration & dosage , Irinotecan*/therapeutic use , Rectal Neoplasms*/therapy , Rectal Neoplasms*/genetics , Rectal Neoplasms*/mortality , Rectal Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Middle Aged ; Female ; Neoadjuvant Therapy/methods ; Aged ; Adult ; Genotype ; Chemoradiotherapy ; Follow-Up Studies ; Treatment Outcome

Maritoclax Overcomes FBW7 Deficiency-Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1.

Autoren: Lin Q Liu S Jiang H et al.

Quelle: Cancer medicine [Cancer Med] 2025 Dec; Vol. 14 (23), pp. e71419.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

MeSH-Schlagworte: F-Box-WD Repeat-Containing Protein 7*/genetics , F-Box-WD Repeat-Containing Protein 7*/deficiency , F-Box-WD Repeat-Containing Protein 7*/metabolism , Myeloid Cell Leukemia Sequence 1 Protein*/metabolism , Myeloid Cell Leukemia Sequence 1 Protein*/antagonists & inhibitors , Myeloid Cell Leukemia Sequence 1 Protein*/genetics , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/metabolism , Irinotecan*/pharmacology , Irinotecan*/therapeutic use , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/genetics , Sulfonamides*/pharmacology, Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Mutation

Self-assembled dual-target ibuprofen-irinotecan conjugate for colorectal cancer therapy.

Autoren: Dai L Wen S Chen Y et al.

Quelle: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2025 Dec 01; Vol. 130, pp. 118367. Date of Electronic Publication: 2025 Aug 20.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/chemistry , Irinotecan*/pharmacology , Irinotecan*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/metabolism , Ibuprofen*/chemistry , Ibuprofen*/pharmacology , Ibuprofen*/therapeutic use , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal*/chemistry , Anti-Inflammatory Agents, Non-Steroidal*/pharmacology, Humans ; Animals ; Mice ; HT29 Cells ; Drug Screening Assays, Antitumor ; Cell Proliferation/drug effects ; Cyclooxygenase 2/metabolism ; Structure-Activity Relationship ; Molecular Structure ; Dose-Response Relationship, Drug ; Nanoparticles/chemistry ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/pathology ; Mice, Nude

Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity.

Autoren: Jin S Zhou A Zhang Q et al.

Quelle: International journal of nanomedicine [Int J Nanomedicine] 2025 Nov 19; Vol. 20, pp. 13857-13869. Date of Electronic Publication: 2025 Nov 19 (Print Publication: 2025).

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/administration & dosage , Irinotecan*/chemistry , Irinotecan*/pharmacology , Metal-Organic Frameworks*/chemistry , Curcumin*/administration & dosage , Curcumin*/chemistry , Curcumin*/pharmacology , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology, Animals ; Mice ; Humans ; Cell Line, Tumor ; Cell Membrane/chemistry ; Drug Delivery Systems/methods ; Mice, Inbred BALB C ; Female ; Antineoplastic Agents/administration & dosage ; Male

Selective PI3Kγ inhibition attenuates chemotherapy-induced intestinal mucositis without compromising the anticancer properties of irinotecan.

Autoren: Cajado AG Lopes MH Rangel GFP et al.

Quelle: European journal of pharmacology [Eur J Pharmacol] 2025 Nov 05; Vol. 1006, pp. 178165. Date of Electronic Publication: 2025 Sep 15.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/adverse effects , Irinotecan*/pharmacology , Mucositis*/chemically induced , Mucositis*/pathology , Mucositis*/prevention & control , Mucositis*/drug therapy , Class Ib Phosphatidylinositol 3-Kinase*/metabolism , Phosphoinositide-3 Kinase Inhibitors*/pharmacology , Antineoplastic Agents*/adverse effects , Intestinal Mucosa*/drug effects , Intestinal Mucosa*/pathology, Animals ; Male ; Mice ; Mice, Inbred C57BL ; Cell Line, Tumor ; Humans

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Autoren: Villaruz LC Jin J Wang H et al.

Quelle: Cancer [Cancer] 2025 Nov 01; Vol. 131 (21), pp. e70157.

Publikationsart: Journal Article; Clinical Trial, Phase I

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/administration & dosage , Irinotecan*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/pharmacokinetics , Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors , Ataxia Telangiectasia Mutated Proteins*/genetics , Neoplasms*/drug therapy , Neoplasms*/genetics , Neoplasms*/pathology , Quinazolines*/administration & dosage , Quinazolines*/adverse effects , Quinazolines*/pharmacokinetics , Pyrazoles*/administration & dosage , Pyrazoles*/adverse effects , Pyrazoles*/pharmacokinetics, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Maximum Tolerated Dose ; DNA Damage/drug effects ; Ataxia Telangiectasia ; Pancreatic Neoplasms/drug therapy ; Isoxazoles ; Pyrazines

Nanosomal Irinotecan Targeting Pancreatic Cancer Cell Surface Neuraminidase-1 Sialidase.

Autoren: Murakami K Yokoi Y Hirane N et al.

Quelle: Advanced healthcare materials [Adv Healthc Mater] 2025 Nov; Vol. 14 (28), pp. e01673. Date of Electronic Publication: 2025 Jul 22.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101581613 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2192-2659 (Electronic) Linking ISSN: 21922640 NLM ISO Abbreviation: Adv Healthc Mater Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/pharmacology , Irinotecan*/chemistry , Neuraminidase*/metabolism , Neuraminidase*/antagonists & inhibitors , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/metabolism , Nanoparticles*/chemistry , Carcinoma, Pancreatic Ductal*/drug therapy , Carcinoma, Pancreatic Ductal*/pathology , Carcinoma, Pancreatic Ductal*/metabolism, Humans ; Animals ; Cell Line, Tumor ; Mice ; Xenograft Model Antitumor Assays ; Mice, Nude

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis.

Autoren: Trovato G Rossini D Guidolin A et al.

Quelle: ESMO open [ESMO Open] 2025 Nov; Vol. 10 (11), pp. 105874. Date of Electronic Publication: 2025 Nov 07.

Publikationsart: Journal Article; Comparative Study; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

MeSH-Schlagworte: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Irinotecan*/therapeutic use , Irinotecan*/administration & dosage, Humans ; Female ; Male ; Fluorouracil/therapeutic use ; Fluorouracil/analogs & derivatives ; Fluorouracil/administration & dosage ; Middle Aged ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Deoxycytidine/administration & dosage ; Leucovorin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Propensity Score ; Aged ; Paclitaxel/therapeutic use ; Paclitaxel/administration & dosage ; Organoplatinum Compounds/therapeutic use ; Oxaloacetates/therapeutic use ; Capecitabine/therapeutic use ; Capecitabine/administration & dosage ; Albumins/therapeutic use ; Adult

SCR Protocol: Folfox protocol; XELOX

Constructing natural phenolic acid mesopores to enhance chemotherapy and reduce accompanied intestinal damage.

Autoren: Miao Y Wang K Cao Y et al.

Quelle: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Oct 10; Vol. 386, pp. 114124. Date of Electronic Publication: 2025 Aug 14.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH-Schlagworte: Depsides*/chemistry , Depsides*/administration & dosage , Irinotecan*/administration & dosage , Irinotecan*/chemistry , Cinnamates*/chemistry , Cinnamates*/administration & dosage , Hydroxybenzoates*/chemistry , Hydroxybenzoates*/administration & dosage , Antineoplastic Agents*/administration & dosage, Animals ; Porosity ; Rosmarinic Acid ; Xylans/chemistry ; Xylans/administration & dosage ; Humans ; Gastrointestinal Microbiome/drug effects ; Drug Delivery Systems ; Nanostructures/chemistry ; Nanostructures/administration & dosage ; Mice ; Male

Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.

Autoren: Yang MH Wu SY Ho IW et al.

Quelle: Cancer medicine [Cancer Med] 2025 Oct; Vol. 14 (20), pp. e71307.

Publikationsart: Journal Article; Clinical Trial, Phase II; Multicenter Study

Info zur Zeitschrift: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

MeSH-Schlagworte: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Irinotecan*/administration & dosage , Irinotecan*/adverse effects , Esophageal Squamous Cell Carcinoma*/drug therapy , Esophageal Squamous Cell Carcinoma*/pathology , Esophageal Squamous Cell Carcinoma*/mortality , Esophageal Squamous Cell Carcinoma*/therapy , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Esophageal Neoplasms*/therapy , Esophageal Neoplasms*/mortality , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Squamous Cell Carcinoma of Head and Neck*/mortality , Squamous Cell Carcinoma of Head and Neck*/therapy , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/pathology , Head and Neck Neoplasms*/therapy , Head and Neck Neoplasms*/mortality, Humans ; Male ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Female ; Middle Aged ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Aged ; Liposomes ; Adult ; Chemoradiotherapy

Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials.

Autoren: Yoo C Saborowski A Hyung J et al.

Quelle: Journal of hepatology [J Hepatol] 2025 Oct; Vol. 83 (4), pp. 909-916. Date of Electronic Publication: 2025 Mar 25.

Publikationsart: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE

MeSH-Schlagworte: Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Biliary Tract Neoplasms*/drug therapy , Biliary Tract Neoplasms*/mortality , Irinotecan*/administration & dosage , Irinotecan*/adverse effects, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Liposomes ; Progression-Free Survival ; Treatment Outcome

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI).

Autoren: Tougeron D Mineur L Zaanan A et al.

Körperschaften: Tougeron D Mineur L Zaanan A et al.

Quelle: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Oct 01; Vol. 228, pp. 115741. Date of Electronic Publication: 2025 Aug 22.

Publikationsart: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Comparative Study

Info zur Zeitschrift: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH-Schlagworte: Paclitaxel*/administration & dosage , Paclitaxel*/adverse effects , Paclitaxel*/therapeutic use , Esophageal Squamous Cell Carcinoma*/drug therapy , Esophageal Squamous Cell Carcinoma*/mortality , Esophageal Squamous Cell Carcinoma*/pathology , Esophageal Squamous Cell Carcinoma*/secondary , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Esophageal Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Fluorouracil*/administration & dosage , Fluorouracil*/adverse effects , Irinotecan*/administration & dosage , Irinotecan*/adverse effects, Humans ; Male ; Female ; Aged ; Middle Aged ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Liposomes

Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus.

Autoren: Amano Y Tanino R Sun R et al.

Quelle: Anticancer research [Anticancer Res] 2025 Dec; Vol. 45 (12), pp. 5287-5297.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/administration & dosage , Irinotecan*/pharmacology , Everolimus*/administration & dosage , Everolimus*/pharmacology , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Small Cell Lung Carcinoma*/blood supply , Neovascularization, Pathologic*/drug therapy , Neovascularization, Pathologic*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/blood supply , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Animals ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Mice ; Administration, Metronomic ; Apoptosis/drug effects ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor A/metabolism ; Cell Survival/drug effects ; Camptothecin/analogs & derivatives ; Camptothecin/administration & dosage ; Cell Proliferation/drug effects ; Angiogenesis

Trabectedin-irinotecan as a potential therapeutic option in desmoplastic small round cell tumor: A small case series.

Autoren: Ferrari A Chiaravalli S Ferrari Bravo W et al.

Quelle: Tumori [Tumori] 2025 Dec; Vol. 111 (6), pp. NP16-NP20. Date of Electronic Publication: 2025 Nov 09.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2038-2529 (Electronic) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE

MeSH-Schlagworte: Trabectedin*/administration & dosage , Irinotecan*/administration & dosage , Desmoplastic Small Round Cell Tumor*/drug therapy , Desmoplastic Small Round Cell Tumor*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Adolescent ; Female ; Child ; Young Adult ; Treatment Outcome ; Quality of Life ; Adult

Carrier-free single-molecule hypoxia-activated nanoprodrug of SN38 with ultrahigh drug loading for pancreatic cancer treatment.

Autoren: Regmi A Elayyan M Nisar S et al.

Quelle: Journal of materials chemistry. B [J Mater Chem B] 2025 Nov 12; Vol. 13 (44), pp. 14416-14424. Date of Electronic Publication: 2025 Nov 12.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101598493 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-7518 (Electronic) Linking ISSN: 2050750X NLM ISO Abbreviation: J Mater Chem B Subsets: MEDLINE

MeSH-Schlagworte: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/metabolism , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemical synthesis , Irinotecan*/pharmacology , Irinotecan*/chemistry , Nanoparticles*/chemistry, Humans ; Animals ; Mice ; Drug Screening Assays, Antitumor ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Particle Size ; Tumor Microenvironment/drug effects

Based on multi-pathway induction of tumor immunogenic death and three-mode highly integrated strategy: a nanocomposite system loaded with irinotecan for colorectal cancer therapy.

Autoren: Lei X Wang Y Zhang X et al.

Quelle: Journal of materials chemistry. B [J Mater Chem B] 2025 Nov 12; Vol. 13 (44), pp. 14338-14353. Date of Electronic Publication: 2025 Nov 12.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101598493 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-7518 (Electronic) Linking ISSN: 2050750X NLM ISO Abbreviation: J Mater Chem B Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/pharmacology , Irinotecan*/chemistry , Irinotecan*/therapeutic use , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Nanocomposites*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Immunogenic Cell Death*/drug effects, Humans ; Animals ; Mice ; Drug Liberation ; Mice, Inbred BALB C ; Drug Screening Assays, Antitumor ; Indoles/chemistry ; Cell Line, Tumor ; Polymers/chemistry ; Particle Size ; Cell Proliferation/drug effects ; Drug Carriers/chemistry

Co-delivery of SN38 and SR717 activates cGAS-STING for near-infrared II image-guided chemoimmunotherapy.

Autoren: Hou X Ren C Zeng X et al.

Quelle: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Oct 10; Vol. 386, pp. 114129. Date of Electronic Publication: 2025 Aug 14.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH-Schlagworte: Nucleotidyltransferases*/metabolism , Membrane Proteins*/metabolism , Membrane Proteins*/agonists , Irinotecan*/administration & dosage , Irinotecan*/therapeutic use , Antineoplastic Agents*/administration & dosage , Neoplasms*/drug therapy , Neoplasms*/immunology , Neoplasms*/diagnostic imaging , Neoplasms*/therapy, Animals ; Immunotherapy/methods ; Mice, Inbred C57BL ; Cell Line, Tumor ; Humans ; Female ; Mice ; Dendritic Cells/drug effects ; Dendritic Cells/immunology

Fabrication of Bioconjugates Clacked Chitosan-Coated SN-38 Liposomal Nanoparticles: Improved Precise Chemotherapy Efficacy in Lung Cancer Cells and Its Apoptosis.

Autoren: Zhang X Sun W Liu C

Quelle: Biotechnology and applied biochemistry [Biotechnol Appl Biochem] 2025 Oct; Vol. 72 (5), pp. 1302-1312. Date of Electronic Publication: 2025 Mar 11.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8609465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1470-8744 (Electronic) Linking ISSN: 08854513 NLM ISO Abbreviation: Biotechnol Appl Biochem Subsets: MEDLINE

MeSH-Schlagworte: Chitosan*/chemistry , Chitosan*/pharmacology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Nanoparticles*/chemistry , Apoptosis*/drug effects , Irinotecan*/chemistry , Irinotecan*/pharmacology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry, Humans ; Liposomes/chemistry ; Cell Line, Tumor ; Trastuzumab/chemistry ; Trastuzumab/pharmacology ; Receptor, ErbB-2/metabolism

The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells.

Autoren: Oh S Kim S Keam B et al.

Quelle: Cancer research and treatment [Cancer Res Treat] 2025 Oct; Vol. 57 (4), pp. 1040-1050. Date of Electronic Publication: 2025 Jan 07.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/genetics , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/pharmacology, Humans ; Drug Synergism ; Cell Line, Tumor ; Apoptosis/drug effects ; DNA Damage/drug effects ; Cell Survival/drug effects ; Phthalazines/pharmacology

Curcumin reverses irinotecan-acquired resistance in DLD1 colorectal cancer cells: Insights from whole transcriptomic data.

Autoren: Gavrilas L Sava O Balacescu L et al.

Quelle: Biochemical pharmacology [Biochem Pharmacol] 2025 Dec; Vol. 242 (Pt 3), pp. 117386. Date of Electronic Publication: 2025 Oct 03.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Irinotecan*/pharmacology , Curcumin*/pharmacology , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/metabolism , Colorectal Neoplasms*/pathology , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/physiology , Transcriptome*/drug effects , Transcriptome*/physiology, Humans ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Apoptosis/drug effects ; Gene Expression Profiling/methods ; Dose-Response Relationship, Drug